Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02134366 · ClinicalTrials.gov registry record · Phase 3
Clobazam Use in Epilepsia Partialis Continua - Pilot Study
A Phase 3 study, sponsored by The Cooper Health System.
- Terminated
- Registry status
- Phase 3
- Development phase
- 7
- Enrollment target
NCT02134366: Clinical Trial Phase 3 study, sponsored by The Cooper Health System.
NCT02134366 is a Phase 3 study that was terminated before completion, run by The Cooper Health System. The registered enrollment target is 7 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02134366, a Phase 3 study, was terminated before completion, sponsored by The Cooper Health System.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether clobazam, brand name Onf®, is more effective as an adjunctive or monotherapy in terminating Epilepsia Partialis Continua (EPC) than either lorazepam and/or clonazepam.
Interventions
- DRUG Clonazepam
- DRUG Lorazepam
- DRUG Clobazam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2014-07 |
| Est. Completion | 2017-07 |
| Phase | Phase 3 |
Why NCT02134366 stopped before completion
NCT02134366 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 3 interventions - of which Clonazepam is the first listed.
NCT02134366 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02134366 about?
NCT02134366 is a clinical study titled "Clobazam Use in Epilepsia Partialis Continua - Pilot Study". The purpose of this study is to evaluate whether clobazam, brand name Onf®, is more effective as an adjunctive or monotherapy in terminating Epilepsia Partialis Continua (EPC) than either lorazepam and/or clonazepam.
What is the current status of trial NCT02134366?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 7 participants. The study started on 2014-07. Estimated completion is 2017-07.
What interventions are being tested in trial NCT02134366?
The interventions under investigation include: Clonazepam (DRUG), Lorazepam (DRUG), Clobazam (DRUG).
Who is sponsoring clinical trial NCT02134366?
This trial is sponsored by The Cooper Health System, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02134366's enrollment target sits among peer trials
7 1995th of 2000 higher than 6 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia